NeuroMetrix (NASDAQ:NURO) Releases Earnings Results

NeuroMetrix (NASDAQ:NURO) released its quarterly earnings results on Tuesday. The medical device company reported ($0.75) EPS for the quarter, RTT News reports. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The company had revenue of $0.59 million for the quarter. During the same quarter last year, the business earned ($1.66) EPS.

NeuroMetrix Trading Up 1.7 %

NURO stock traded up $0.06 during mid-day trading on Wednesday, reaching $3.61. 10,833 shares of the stock traded hands, compared to its average volume of 26,234. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The stock’s fifty day moving average is $4.04 and its 200-day moving average is $3.88. The company has a market cap of $7.33 million, a P/E ratio of -0.65 and a beta of 2.29.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of NeuroMetrix in a research report on Monday. They issued a “sell” rating on the stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.